

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) An isolated nucleic acid molecule selected from the group comprising:
  - a) a nucleic acid molecule comprising a nucleotide sequence according to SEQ ID No. 1,
  - b) a nucleic acid molecule comprising a nucleotide sequence having sufficient homology to be functionally analogous to a nucleotide sequence according to a),
  - c) a nucleic acid molecule which, as a consequence of the genetic code, is degenerated into a nucleotide sequence according to a) or b), and
  - d) a nucleic acid molecule according to a nucleotide sequence of a) - c), which is modified and functionally analogous to a nucleotide sequence according to a) through c) as a result of deletions, additions, substitutions, translocations, inversions and/or insertions.
2. (Original) The nucleic acid molecule according to claim 1, characterized in that the nucleotide sequence specified under b) has at least 80%, preferably 90% homology to a nucleotide sequence as specified under a).
3. (Currently Amended) The nucleic acid molecule according to claim 1 ~~or 2~~, characterized in that said molecule is a genomic DNA, a cDNA and/or an RNA.
4. (Currently Amended) A vector comprising a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1.
5. (Original) A host cell comprising the vector according to claim 4.
6. (Currently Amended) A polypeptide encoded by a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1.
7. (Currently Amended) A recognition molecule directed against a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1 ~~or, a vector according to claim 4, or a host~~

- cell ~~according to claim 5 and/~~ based thereon or a polypeptide ~~according to claim 6~~ encoded thereby.
8. (Original) The recognition molecule according to claim 7, characterized in that said molecule is an antibody, an antibody fragment and/or an antisense construct, particularly an RNA interference molecule.
  9. (Currently Amended) A pharmaceutical composition, characterized in that said composition comprises a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1, a vector ~~according to claim 4, or~~ a host cell ~~according to claim 5~~ based thereon, a polypeptide ~~according to claim 6 and/~~ encoded thereby or a recognition molecule ~~according to any of claims 7 or 8~~ corresponding thereto, optionally together with a pharmaceutically tolerable carrier.
  10. (Currently Amended) A kit, characterized in that said kit comprises a nucleic acid molecule according to any of claims 1 to 3, a vector according to claim 4, a host cell according to claim 5, a polypeptide according to claim 6, a recognition molecule according to any of claims 7 or 8, optionally together with a pharmaceutically tolerable carrier, and/or the pharmaceutical composition according to claim 9.
  11. (Currently Amended) A method for the detection of an AKAP-PKA interaction, comprising the steps of:
    - a) providing (i) a first vector comprising a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1 and a first marker, and (ii) a second vector comprising a second nucleic acid molecule which encodes a regulatory subunit of a protein kinase and a second marker,
    - b) incorporating the first and second markers in a cell, thereby transfecting the cell, and
    - c) performing a fluorescence resonance energy transfer (FRET) measurement, thereby detecting the AKAP-PKA interaction.
  12. (Original) The method according to claim 11, characterized in that interaction between AKAP and RII $\alpha$ , RII $\beta$ , RI $\alpha$  and/or RI $\beta$  is detected.

13. (Currently Amended) The method according to ~~any of claims 11 or 12~~ Claim 11, characterized in that an inhibitor of AKAP and/or a PKA is identified in such a way that the method is performed with and without addition of the inhibitor to be investigated, thereby providing an indication as to the inhibitor of AKAP and/or PKA.
14. (Currently Amended) The method according to ~~any of claims 11 to 13~~ Claim 11, characterized in that a membrane-permeable molecule is identified in such a way that a conjugate of the membrane-permeable molecule to be investigated and a membrane-permeable AKAP-PKA inhibitor is produced and AKAP-PKA interaction is detected with and without said conjugate or said molecule.
15. (Currently Amended) Use of a nucleic acid molecule according to ~~any of claims 1 to 3~~ Claim 1, a vector ~~according to claim 4~~, or a host cell ~~according to claim 5~~ based thereon, a polypeptide ~~according to claim 6~~ encoded thereby, a recognition molecule ~~according to claim 7 or 8~~ corresponding thereto, a pharmaceutical composition ~~according to claim 9~~ based thereon, a kit ~~according to claim 10 and/~~ based thereon or a method ~~according to any of claims 11 to 14~~ for the detection of an AKAP-PKA interaction or of an inhibitor of AKAP and/or PKA and/or of a membrane-permeable peptide.